Well-characterized PDX models, with accompanying genome sequencing and gene expression data, can help researchers elucidate mechanisms of action of their lead compound.
TORONTO (PRWEB) April 28, 2020
Less than 10% of investigational anti-cancer drugs successfully achieve approval for clinical use by the FDA. This is not necessarily due to the lack of activity of the compound, but is instead due to a failure to identify patients whose tumors are most likely to respond. Recent research has focused on developing new models that better recapitulate what can be seen in the clinic. One group of such models is the patient-derived xenografts (PDXs).
PDXs are established by directly implanting tumor tissue into an immunocompromised host, most commonly mice, without intermittent passaging of the cells in culture. Increasing evidence indicated that these PDXs not only faithfully conserve biological features of the parental malignancies but also show sensitivity/resistance to the same therapeutic agents. Well-characterized PDX models, with accompanying genome sequencing and gene expression data, can help researchers elucidate mechanisms of action of their lead compound.
Envigo offers access to more than 100 highly-characterized breast cancer PDX models representing all major subtypes through its licensed WHIM (Washington University Human in Mouse) collection from Washington University in St. Louis. This collection of breast cancer tumors offer investigators a powerful tool to test novel drugs in a model where the clinical history of the patient and the mutational landscape of both the parental and PDX tumor is known.
For more information or to register for this event, visit Patient-Derived Xenografts: A Powerful Tool for Breast Cancer Research and Beyond.
Envigo provides the broadest range of research models and related services to the pharmaceutical and biotechnology industries, government, academia, and other life science organizations. As the largest organization that is solely dedicated to providing research models and related products and services, we are committed to helping researchers realize the full potential of their critical R&D projects as we fulfill our mission to work together to build a healthier and safer world. Read more at envigo.com.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.